Axsome Therapeutics Inc (NASDAQ:AXSM)
| 81.75 Delayed Data As of Sep 18 |  +2.67 / +3.38%Today’s Change | 13.64 Today|||52-Week Range 109.94 | -20.91% Year-to-Date |
Latest AXSM News | Press Releases
| Axsome +20% as depression drug shows improvement in patient outcomes Sep 14 / Seeking Alpha - Paid Partner Content | Axsome (AXSM) Down 10.4% Since Last Earnings Report: Can It Rebound? Sep 09 / Zacks.com - Paid Partner Content |
| 2 Biotech Stocks with Jaw-Dropping Growth Potential Sep 13 / MotleyFool.com - Paid Partner Content | Axsome Therapeutics reports development plans of AXS-05 for Alzheimer’s disease agitation Aug 31 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 79.08 |
| Today’s open | 80.84 |
| Day’s range | 79.39 - 83.00 |
| Volume | 18,300 |
| Average volume (3 months) | 501,003 |
| Market cap | $3.0B |
Data as of 4:00pm ET, 09/18/2020
Growth & Valuation
| Earnings growth (last year) | -74.42% |
| Earnings growth (this year) | -29.05% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 16.87 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TWSTTwist Bioscience Cor... | +2.98 | +4.60% |
| DCPHDeciphera Pharmaceut... | +3.51 | +6.68% |
| ---- | ||
| FATEFate Therapeutics In... | +2.39 | +6.48% |
Data as of 3:59pm ET, 09/18/2020
Financials
| Next reporting date | November 5, 2020 |
| EPS forecast (this quarter) | -$0.55 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$68.3M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
No executives to display |
Corporate headquarters New York, New York |
Forecasts
